CONCENTRATION OF RISK	9 Months Ended
CONCENTRATION OF RISK	Sep. 30, 2013
Risks and Uncertainties [Abstract]
Concentration Risk	CONCENTRATION OF RISK Customer and Credit Risk The Company provides trade credit to its customers in the normal course of business. One payor accounted for approximately 20% and 20% of revenue during the three months ended September 30, 2013 and 2012, and approximately 20% and 18% during the nine months ended September 30, 2013 and 2012, respectively. The majority of the revenue is related to the Infusion Services segment. Therapy Revenue Risk The Company sells products related to the Immune Globulin therapy, which represented 18% and 18% of revenue during the three months ended September 30, 2013 and 2012, and 18% and 20% during the nine months ended September 30, 2013 and 2012, respectively. The revenue is related to the Infusion Services segment.

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details